论文部分内容阅读
目的观察冻干重组人脑利钠肽(Lyophilized Recombinant Human Brain Natriuretic Peptide,Lrh-BNP)与米力农(Milrinone)治疗围产期心肌病(peripartum cardiomyopathy,PPCM)的疗效。方法对52例PPCM患者在基础抗心衰治疗上分别应用米力农和Lrh-BNP治疗。结果 Lrh-BNP组总有效率(93.5%)显著高于米力农组(79%);两组治疗前后左心室射血分数(LVEF)、左心室短轴缩短率(Fs)、舒张早期最大充盈速度(E)与舒张晚期最大充盈速度(A)的比值(E/A)、每搏输出量(SV)、心输出量(CO)、24小时尿量、呼吸困难均可得到明显的改善。但Lrh-BNP可以更明显地改善心功能、不增加心率、不降低平均动脉压(MAP)。结论 Lrh-BNP可以更明显地改善PPCM患者心功能,具有更高的临床有效率,且无明显的毒副作用。
Objective To observe the effect of lyophilized recombinant human brain Natriuretic Peptide (Lrh-BNP) and milrinone on peripartum cardiomyopathy (PPCM). Methods Fifty-two patients with PPCM were treated with Milrinone and Lrh-BNP respectively in the treatment of basal anti-heart failure. Results The total effective rate (93.5%) in Lrh-BNP group was significantly higher than that in milrinone group (79%). The left ventricular ejection fraction (LVEF), left ventricular fractional shortening (Fs) (E / A), stroke volume (SV), cardiac output (CO), 24-hour urine output and dyspnea were all significantly improved . However, Lrh-BNP improved heart function more significantly without increasing heart rate and without lowering mean arterial pressure (MAP). Conclusion Lrh-BNP can significantly improve cardiac function in patients with PPCM, with higher clinical efficiency, and no obvious side effects.